Pangaea Oncology (XMAD:PANG) ROCE % : -14.41% (As of Jun. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Pangaea Oncology ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Pangaea Oncology's annualized ROCE % for the quarter that ended in Jun. 2024 was -14.41%.

Pangaea Oncology ROCE % Historical Data

The historical data trend for Pangaea Oncology's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pangaea Oncology ROCE % Chart

Pangaea Oncology Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-35.31

-13.87

-5.64

-12.23

-14.26

Pangaea Oncology Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
ROCE %	Get a 7-Day Free Trial															-5.19	-14.92	-6.60	-23.85	-14.41

Pangaea Oncology ROCE % Calculation

Pangaea Oncology's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-3.373	/	( ( (28.377 - 2.724)	+	(28.834 - 7.175) )	/ 2 )
	=	-3.373	/	( (25.653	+	21.659)	/ 2 )
	=	-3.373	/	23.656
	=	-14.26 %

Pangaea Oncology's ROCE % of for the quarter that ended in Jun. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	-2.976	/	( ( (28.834 - 7.175)	+	(26.868 - 7.23) )	/ 2 )
	=	-2.976	/	( ( 21.659	+	19.638 )	/ 2 )
	=	-2.976	/	20.6485
	=	-14.41 %

(1) Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

Pangaea Oncology (XMAD:PANG) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Pangaea Oncology ROCE % Related Terms

Thank you for viewing the detailed overview of Pangaea Oncology's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Pangaea Oncology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Pangaea Oncology SA (XMAD:PANG) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Calle Sabino Arana, 5-19, Barcelona, ESP, 08028

Website

http://www.panoncology.com

Pangaea Oncology SA is a medical services company. The company provides a wide range of services to cancer patients, as well as global pharmaceutical and biotech clients, in the fields of molecular diagnostics, clinical trials, in vitro drug profiling, dx platform validation, and biomarker discovery. The company has aggregated its operations into two segments, Clinical Care division and Diagnostic and Research and Development services division. Clinical Care division delivers medical oncology services and related activities. Diagnostic and Research and Development services division provides diagnostic and in-vitro services.

Pangaea Oncology Headlines

No Headlines